Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RGNX – REGENXBIO Inc.

Float Short %

11.07

Margin Of Safety %

Put/Call OI Ratio

0.74

EPS Next Q Diff

-0.19

EPS Last/This Y

1.33

EPS This/Next Y

1.19

Price

15.24

Target Price

32.67

Analyst Recom

1.42

Performance Q

45

Relative Volume

1.34

Beta

1.05

Ticker: RGNX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-09RGNX12.730.850.384340
2025-12-10RGNX13.080.841.444361
2025-12-11RGNX12.870.840.264360
2025-12-12RGNX13.880.830.874372
2025-12-15RGNX13.830.830.055126
2025-12-16RGNX14.120.800.005287
2025-12-17RGNX13.180.780.905330
2025-12-18RGNX13.50.770.075303
2025-12-19RGNX14.580.770.295310
2025-12-22RGNX14.980.710.594800
2025-12-23RGNX14.350.718.004841
2025-12-26RGNX14.180.710.744858
2025-12-29RGNX14.310.720.354878
2025-12-30RGNX14.10.720.074889
2025-12-31RGNX14.410.740.004987
2026-01-02RGNX13.570.741.505001
2026-01-05RGNX13.390.780.135223
2026-01-06RGNX14.170.750.005367
2026-01-07RGNX15.250.740.025390
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-09RGNX12.7221.1236.4-3.26
2025-12-10RGNX13.0721.1246.4-3.26
2025-12-11RGNX12.8621.1239.8-3.26
2025-12-12RGNX13.8821.1254.5-3.26
2025-12-15RGNX13.8321.1241.9-3.26
2025-12-16RGNX13.8321.1245.4-3.26
2025-12-17RGNX13.1621.1232.4-3.26
2025-12-18RGNX13.5021.1246.0-3.26
2025-12-19RGNX14.5721.0254.2-3.26
2025-12-22RGNX15.1421.0247.3-3.26
2025-12-23RGNX14.3121.0235.6-3.26
2025-12-26RGNX14.1821.0239.6-3.26
2025-12-29RGNX14.2721.0243.4-3.26
2025-12-30RGNX14.1021.0240.2-3.26
2025-12-31RGNX14.4021.0245.5-3.26
2026-01-02RGNX13.5721.0233.8-3.26
2026-01-05RGNX13.4021.0240.3-3.26
2026-01-06RGNX14.1621.0250.8-3.26
2026-01-07RGNX15.2421.0253.2-3.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-09RGNX-0.80-1.2210.28
2025-12-10RGNX-0.80-1.2211.76
2025-12-11RGNX-0.80-1.2211.76
2025-12-12RGNX-0.80-1.2211.76
2025-12-15RGNX-0.80-1.2111.76
2025-12-16RGNX-0.80-1.2111.76
2025-12-17RGNX-0.80-1.2111.76
2025-12-18RGNX-0.80-1.2111.76
2025-12-19RGNX-0.80-1.2111.76
2025-12-22RGNX-0.80-1.2111.76
2025-12-23RGNX-0.80-1.2111.76
2025-12-26RGNX-0.80-1.2111.07
2025-12-29RGNX-0.80-1.2111.07
2025-12-30RGNX-0.80-1.2111.07
2025-12-31RGNX-0.80-1.2111.07
2026-01-02RGNX-0.80-1.2111.07
2026-01-05RGNX-0.80-1.2111.07
2026-01-06RGNX-0.80-1.2111.07
2026-01-07RGNX-0.80-1.2111.07
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-1.2

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-1.39

Insider Transactions

-0.8

Institutional Transactions

-1.21

Beta

1.05

Average Sales Estimate Current Quarter

61

Average Sales Estimate Next Quarter

68

Fair Value

Quality Score

39

Growth Score

46

Sentiment Score

74

Actual DrawDown %

69.7

Max Drawdown 5-Year %

-89.4

Target Price

32.67

P/E

Forward P/E

PEG

P/S

4.78

P/B

4.78

P/Free Cash Flow

EPS

-3.49

Average EPS Est. Cur. Y​

-3.26

EPS Next Y. (Est.)

-2.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-110.29

Relative Volume

1.34

Return on Equity vs Sector %

-137.3

Return on Equity vs Industry %

-122.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.06

EBIT Estimation

253.2
REGENXBIO Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading